Chronic Kidney Disease
Conditions
Keywords
URAT1 inhibitor, Uric acid transporter 1, Verinurad, Crossover study, Relative bioavailability, Pharmacokinetics
Brief summary
This study is intended to assess the relative bioavailability between the (extended-release) ER8 capsule formulation (the formulation that is currently used for verinurad development) given under fasted conditions and 2 new capsule formulations of verinurad (A-capsule and B-capsule) given under fed or fasted conditions. All three capsules target an 8-hour release profile (extended-release). The highest dose (12 mg) currently tested in participants will be tested in this study. The study is designed to provide information to optimize the verinurad part of a fixed dose combination capsule to be used in future development.
Detailed description
This study will be a randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female participants, performed at a single study centre. This study is intended to assess the relative bioavailability between the ER8 capsule formulation (the formulation that is currently used for verinurad development) given under fasted conditions and 2 new capsule formulation of verinurad (A-capsule and B-capsule) given under fed or fasted conditions. All three capsules target an 8-hour release profile (extended-release). The highest dose (12 mg) currently tested in participants will be tested in this study. The study is designed to provide information to optimize the verinurad part of a fixed dose combination capsule to be used in future development. The study will comprise: a screening period of maximum 28 days; five treatment periods during which participants will be resident from the morning of the day before dosing with verinurad (Day -1) until at least 72 hours after dosing; discharged on the morning of Day 4 of each Treatment Period; and a follow-up Visit within 7 to 14 days after the last administration of verinurad. There will be a minimum washout period of 5 days between each dose administration. A total of 25 healthy male and female participants will be randomised into this study. Each participant will receive five single-dose treatments of 12 mg verinurad with 240 mL water, following an overnight fast of at least 10 hours. Participants will follow an overnight fast of at least 10 hours before the dosing procedures: for the fed dosing, a high-fat, high-calorie standard breakfast will be served 30 minutes before the planned administration of verinurad to be consumed in full at least 5 minutes before dosing; for the fasted dosing, no breakfast will be served. A meal can be given 4 hours after administration of verinurad for both dosing states. The duration of the study is expected to be approximately 9 weeks for each individual participant (including the 28-day screening period).
Interventions
DRUGVerinurad ER8 capsule formulation (fasted)
Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
DRUGVerinurad A-capsule formulation (fasted)
Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
DRUGVerinurad A-capsule formulation (fed)
Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
DRUGVerinurad B-capsule formulation (fasted)
Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
DRUGVerinurad B-capsule formulation (fed)
Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male and female participants aged 18 to 50 years with suitable veins for cannulation or repeated venepuncture. 3. Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg. 4. Females must have a negative pregnancy test at screening and on admission to the unit and must be: (1) not pregnant or currently lactating or breastfeeding. (2) of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria: (i) postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range (FSH levels \> 40 IU/mL). (ii) documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. (3) OR if of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy for the entire study period.
Exclusion criteria
1. History of gout or any clinically significant disease or disorder which, in the opinion of the Principal Investigator (PI), may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study. 2. Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of verinurad. 3. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. 4. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results as judged by the Investigator at screening and first admission, including: (1) Alanine aminotransferase (ALT) \> 1.5 x upper limit of normal (ULN), (2) Aspartate aminotransferase (AST) \> 1.5 x ULN, (3) Bilirubin (total) \> 1.5 x ULN, (4) Gamma glutamyl transpeptidase (GGT) \> 1.5 x ULN. (5) If any of these tests are out-of-range, the tests can be repeated once. 5. Any clinically significant abnormal findings in vital signs at the Screening Visit and/or admission to the Clinical Unit, including, but not limited to, any of the following: (1) Heart rate (resting, supine) \< 50 beats per minute (bpm) or \> 85 bpm, (2) Systolic BP \< 90 mmHg or \> 140 mmHg and/or diastolic BP \< 50 mmHg or \> 90 mmHg sustained for \> 10 min while resting in a supine position. 6\. Any clinically significant abnormalities on 12-lead Electrocardiogram (ECG) at the Screening Visit, including, but not limited to any of the following: 1. ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for heart rate using Fridericia's formula (QTcF) \> 450 ms or \< 340 ms or family history of long QT syndrome, 2. Any significant arrhythmia, 3. Conduction abnormalities: 4. Clinically significant PR (PQ) interval prolongation (\> 240 ms); intermittent second or third degree atrioventricular (AV) block, or AV dissociation, 5. Complete bundle branch block and/or QRS duration \> 120 ms. 7. Any positive result at the Screening Visit for serum hepatitis B surface antigen or antiHBc antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody. 8\. Suspicion or known Gilbert's and/or Lesch-Nyhan syndrome. 9. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI. Excessive intake of alcohol defined as the regular consumption of more than 24 g of alcohol per day for men or 12 g of alcohol per day for women. 10\. Has received another new chemical entity (defined as a compound which has not been approved for marketing in the US) within 30 days or at least 5 half-lives (whichever is longer) of the first administration of verinurad in this study. 11\. Participants who have previously received verinurad. 12. Plasma donation within 1 month of screening or any blood donation/loss of more than 500 mL during the 3 months prior to the Screening Visit. 13\. Participants who are pregnant, lactating or planning to become pregnant. 14. History of severe allergy/hypersensitivity or ongoing clinically relevant allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to verinurad. 15\. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening. 16\. Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the PI. Excessive intake of caffeine defined as regular consumption of more than 600 mg of caffeine per day (e.g., \> 5 cups of coffee) or would likely be unable to refrain from the use of caffeine containing beverages during confinement at the investigational site. 17\. Positive screen for drugs of abuse or cotinine (nicotine) at the Screening Visit or positive screen for alcohol, drugs of abuse and cotinine on each admission to the study centre. 18\. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of verinurad. 19\. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of verinurad or longer if the medication has a long half-life. The use of hormonal contraception therapy and hormonal replacement therapy for females are permitted. 20\. Any AstraZeneca, PAREXEL or study site employee or their close relatives. 21. Participants who cannot communicate reliably with the PI and/or is not able to read, speak and understand the German language. 22\. Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements. 23\. Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order. 24\. Participants with any special dietary restrictions such as participants that are lactose intolerant or are vegetarians/vegans.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) | Day 1: Pre-dose and up to 72-hour Post-dose | To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions. |
| AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions. |
| Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
| Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
| Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
| AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter | Pre-dose and up to 24-hours Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
| Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
| Number of Participants With Adverse Events (AEs) | From screening (Day -28 to Day -2) till follow-up visit (7 to 14 days post-final dose) | To assess AEs as variable of safety and tolerability of single doses of verinurad in healthy participants. |
| Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
| Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter | Day 1: Pre-dose and up to 72-hour Post-dose | To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions. |
Countries
Germany
Participant flow
Recruitment details
All subjects signed and dated the informed consent form (ICF) before any study procedures were performed.
Pre-assignment details
The study included a Screening Period of maximum 28 days.
Participants by arm
| Arm | Count |
|---|---|
| Overall-All Subjects All subjects were randomized into 5-period, 5-treatment, crossover study to receive a single oral dose of 12 mg verinurad:
* Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted.
* Treatment 2: 2 x 6 mg verinurad A-capsule formulation, fasted.
* Treatment 3: 2 x 6 mg verinurad A-capsule formulation, fed.
* Treatment 4: 2 x 6 mg verinurad B-capsule formulation, fasted.
* Treatment 5: 2 x 6 mg verinurad B-capsule formulation, fed. | 25 |
| Total | 25 |
Baseline characteristics
| Characteristic | Overall-All Subjects |
|---|---|
| Age, Continuous | 38.1 Years STANDARD_DEVIATION 9.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 25 Participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 |
| other Total, other adverse events | 5 / 25 | 6 / 25 | 2 / 25 | 4 / 25 | 3 / 25 |
| serious Total, serious adverse events | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 | 0 / 25 |
Outcome results
Primary
Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC)
To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) | 171.3 ng*h/mL | Geometric Coefficient of Variation 47.6 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) | 167.5 ng*h/mL | Geometric Coefficient of Variation 33.72 |
| Treatment 3: 2 x 6 mg A-capsule Fed | Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) | 87.14 ng*h/mL | Geometric Coefficient of Variation 65.84 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) | 149.0 ng*h/mL | Geometric Coefficient of Variation 39.78 |
| Treatment 5: 2 x 6 mg B-capsule Fed | Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) | 150.2 ng*h/mL | Geometric Coefficient of Variation 42.57 |
Comparison: Pairwise comparison: Treatment 2/Treatment 190% CI: [91.73, 122.96]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 190% CI: [42.34, 59.1]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 290% CI: [39.85, 55.68]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 490% CI: [49.49, 68.92]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 4/Treatment 190% CI: [73.78, 99.43]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 4/Treatment 290% CI: [69.48, 93.62]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 190% CI: [77.61, 104.09]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 290% CI: [72.94, 98.2]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 390% CI: [151.57, 212.99]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 490% CI: [90.18, 122.11]Mixed Model Analysis
Primary
AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter
To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter | 166.8 ng*h/mL | Geometric Coefficient of Variation 47.57 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter | 167.5 ng*h/mL | Geometric Coefficient of Variation 35.96 |
| Treatment 3: 2 x 6 mg A-capsule Fed | AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter | 67.04 ng*h/mL | Geometric Coefficient of Variation 80.37 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter | 128.5 ng*h/mL | Geometric Coefficient of Variation 49.29 |
| Treatment 5: 2 x 6 mg B-capsule Fed | AUC From Time 0 to the Last Quantifiable Concentration (AUC0-t) for the Analysis of PK Parameter | 139.6 ng*h/mL | Geometric Coefficient of Variation 44.36 |
Comparison: Pairwise comparison: Treatment 2/Treatment 190% CI: [84.94, 118.65]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 190% CI: [34.74, 49]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 290% CI: [34.61, 48.81]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 490% CI: [45.09, 63.59]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 4/Treatment 190% CI: [65.19, 91.06]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 4/Treatment 290% CI: [64.94, 90.71]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 190% CI: [70.93, 100.03]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 290% CI: [70.65, 99.64]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 390% CI: [171.22, 243.42]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 490% CI: [92.06, 129.83]Mixed Model Analysis
Primary
Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter
To evaluate the relative bioavailability between the A-capsule and B-capsule formulations under both fed and fasted conditions with the ER8 capsule formulation under fasted conditions and with each other under the same food conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter | 25.51 ng/mL | Geometric Coefficient of Variation 53.66 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter | 31.88 ng/mL | Geometric Coefficient of Variation 62.41 |
| Treatment 3: 2 x 6 mg A-capsule Fed | Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter | 8.243 ng/mL | Geometric Coefficient of Variation 81.12 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter | 23.39 ng/mL | Geometric Coefficient of Variation 66.08 |
| Treatment 5: 2 x 6 mg B-capsule Fed | Maximum Observed Plasma Concentration (Cmax) for the Analysis of PK Parameter | 17.02 ng/mL | Geometric Coefficient of Variation 54 |
Comparison: Pairwise comparison: Treatment 2/Treatment 190% CI: [101.09, 154.54]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 190% CI: [27.15, 42.01]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 290% CI: [21.72, 33.61]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 3/Treatment 490% CI: [29.61, 45.82]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 4/Treatment 190% CI: [74.15, 113.36]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 4/Treatment 290% CI: [59.33, 90.7]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 190% CI: [54.37, 84.12]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 290% CI: [43.5, 67.3]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 390% CI: [160.15, 250.32]Mixed Model Analysis
Comparison: Pairwise comparison: Treatment 5/Treatment 490% CI: [59.3, 91.75]Mixed Model Analysis
Secondary
Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter | 77.86 Litre/hour | Standard Deviation 42.15 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter | 75.43 Litre/hour | Standard Deviation 25.71 |
| Treatment 3: 2 x 6 mg A-capsule Fed | Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter | 160.5 Litre/hour | Standard Deviation 86.96 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter | 86.26 Litre/hour | Standard Deviation 32.22 |
| Treatment 5: 2 x 6 mg B-capsule Fed | Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for the Analysis of PK Parameter | 87.10 Litre/hour | Standard Deviation 41.78 |
Secondary
Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter | 1529 Litre | Standard Deviation 953.1 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter | 1490 Litre | Standard Deviation 779.9 |
| Treatment 3: 2 x 6 mg A-capsule Fed | Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter | 3120 Litre | Standard Deviation 2066 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter | 1810 Litre | Standard Deviation 1120 |
| Treatment 5: 2 x 6 mg B-capsule Fed | Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for the Analysis of PK Parameter | 1719 Litre | Standard Deviation 1608 |
Secondary
AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Pre-dose and up to 24-hours Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter | 132.6 ng*h/mL | Geometric Coefficient of Variation 48.4 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter | 138.5 ng*h/mL | Geometric Coefficient of Variation 39.67 |
| Treatment 3: 2 x 6 mg A-capsule Fed | AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter | 54.85 ng*h/mL | Geometric Coefficient of Variation 80.02 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter | 102.9 ng*h/mL | Geometric Coefficient of Variation 54.45 |
| Treatment 5: 2 x 6 mg B-capsule Fed | AUC From Time 0 to 24 Hours Post Dose (AUC0-24) for the Analysis of PK Parameter | 110.6 ng*h/mL | Geometric Coefficient of Variation 47.83 |
Secondary
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter | 14.02 Hour | Standard Deviation 4.732 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter | 13.61 Hour | Standard Deviation 5.748 |
| Treatment 3: 2 x 6 mg A-capsule Fed | Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter | 13.42 Hour | Standard Deviation 5.549 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter | 14.36 Hour | Standard Deviation 5.477 |
| Treatment 5: 2 x 6 mg B-capsule Fed | Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) for the Analysis of PK Parameter | 12.40 Hour | Standard Deviation 5.038 |
Secondary
Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter | 16.98 Hour | Standard Deviation 4.006 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter | 15.52 Hour | Standard Deviation 5.843 |
| Treatment 3: 2 x 6 mg A-capsule Fed | Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter | 17.43 Hour | Standard Deviation 4.974 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter | 16.61 Hour | Standard Deviation 6.049 |
| Treatment 5: 2 x 6 mg B-capsule Fed | Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRT) for the Analysis of PK Parameter | 18.28 Hour | Standard Deviation 4.841 |
Secondary
Number of Participants With Adverse Events (AEs)
To assess AEs as variable of safety and tolerability of single doses of verinurad in healthy participants.
Time frame: From screening (Day -28 to Day -2) till follow-up visit (7 to 14 days post-final dose)
Population: All subjects who received at least 1 dose of verinurad (any formulation) were included in the safety analysis for the study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Number of Participants With Adverse Events (AEs) | Any TEAE leading to discontinuation of IMP | 0 Participants |
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Number of Participants With Adverse Events (AEs) | Any treatment emergent adverse event (TEAE) | 5 Participants |
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Number of Participants With Adverse Events (AEs) | Any TEAE leading to withdrawal from study | 0 Participants |
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Number of Participants With Adverse Events (AEs) | Related TEAEs | 2 Participants |
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Number of Participants With Adverse Events (AEs) | Any serious TEAE (including death) | 0 Participants |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any TEAE leading to discontinuation of IMP | 0 Participants |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any serious TEAE (including death) | 0 Participants |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Number of Participants With Adverse Events (AEs) | Related TEAEs | 0 Participants |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any TEAE leading to withdrawal from study | 0 Participants |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any treatment emergent adverse event (TEAE) | 6 Participants |
| Treatment 3: 2 x 6 mg A-capsule Fed | Number of Participants With Adverse Events (AEs) | Any serious TEAE (including death) | 0 Participants |
| Treatment 3: 2 x 6 mg A-capsule Fed | Number of Participants With Adverse Events (AEs) | Any treatment emergent adverse event (TEAE) | 2 Participants |
| Treatment 3: 2 x 6 mg A-capsule Fed | Number of Participants With Adverse Events (AEs) | Related TEAEs | 1 Participants |
| Treatment 3: 2 x 6 mg A-capsule Fed | Number of Participants With Adverse Events (AEs) | Any TEAE leading to discontinuation of IMP | 0 Participants |
| Treatment 3: 2 x 6 mg A-capsule Fed | Number of Participants With Adverse Events (AEs) | Any TEAE leading to withdrawal from study | 0 Participants |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any TEAE leading to withdrawal from study | 0 Participants |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any treatment emergent adverse event (TEAE) | 4 Participants |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any TEAE leading to discontinuation of IMP | 0 Participants |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Number of Participants With Adverse Events (AEs) | Any serious TEAE (including death) | 0 Participants |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Number of Participants With Adverse Events (AEs) | Related TEAEs | 3 Participants |
| Treatment 5: 2 x 6 mg B-capsule Fed | Number of Participants With Adverse Events (AEs) | Any serious TEAE (including death) | 0 Participants |
| Treatment 5: 2 x 6 mg B-capsule Fed | Number of Participants With Adverse Events (AEs) | Any TEAE leading to discontinuation of IMP | 0 Participants |
| Treatment 5: 2 x 6 mg B-capsule Fed | Number of Participants With Adverse Events (AEs) | Any treatment emergent adverse event (TEAE) | 3 Participants |
| Treatment 5: 2 x 6 mg B-capsule Fed | Number of Participants With Adverse Events (AEs) | Any TEAE leading to withdrawal from study | 0 Participants |
| Treatment 5: 2 x 6 mg B-capsule Fed | Number of Participants With Adverse Events (AEs) | Related TEAEs | 0 Participants |
Secondary
Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter | 71.65 Hour |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter | 48.47 Hour |
| Treatment 3: 2 x 6 mg A-capsule Fed | Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter | 47.97 Hour |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter | 48.03 Hour |
| Treatment 5: 2 x 6 mg B-capsule Fed | Time of Last Quantifiable Plasma Concentration (Tlast) for the Analysis of PK Parameter | 48.03 Hour |
Secondary
Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter | 4.98 Hour |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter | 4.98 Hour |
| Treatment 3: 2 x 6 mg A-capsule Fed | Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter | 5.00 Hour |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter | 4.00 Hour |
| Treatment 5: 2 x 6 mg B-capsule Fed | Time to Reach Maximum Observed Plasma Concentration (Tmax) for the Analysis of PK Parameter | 7.98 Hour |
Secondary
Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter
To examine the PK profiles of verinurad when administered as the 3 different capsule formulations under fasted conditions.
Time frame: Day 1: Pre-dose and up to 72-hour Post-dose
Population: The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations thought to impact on the analysis of the PK data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment 1: 1 x 12 mg ER8 Capsule Fasted | Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter | 1275 Litre | Standard Deviation 612.8 |
| Treatment 2: 2 x 6 mg A-capsule Fasted | Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter | 1190 Litre | Standard Deviation 586.4 |
| Treatment 3: 2 x 6 mg A-capsule Fed | Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter | 2756 Litre | Standard Deviation 1577 |
| Treatment 4: 2 x 6 mg B-capsule Fasted | Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter | 1472 Litre | Standard Deviation 855.9 |
| Treatment 5: 2 x 6 mg B-capsule Fed | Volume of Distribution at Steady State (Intravenous Dosing) (Vss/F) for the Analysis of PK Parameter | 1645 Litre | Standard Deviation 1157 |